Literature DB >> 2112564

Administration of bacterial lipopolysaccharide elicits circulating tumor necrosis factor-alpha in neonatal calves.

J L Adams1, S D Semrad, C J Czuprynski.   

Abstract

The presence of tumor necrosis factor-alpha (TNF-alpha) during endotoxemia in ruminants has not been reported previously. In this study, we detected the in vivo release of bovine TNF-alpha by using WEHI-164 murine fibrosarcoma cells as targets in an 18-h cytotoxicity assay. Treatment of the WEHI-164 cells with 1 microgram of actinomycin D (dactinomycin) enhanced approximately twofold the susceptibility of the cells to TNF-alpha activity. TNF-alpha activity in sera from neonatal calves injected intravenously with 2.7 micrograms of Escherichia coli lipopolysaccharide (LPS) increased rapidly within the first 2 h postinjection and then declined until it was undetectable by 4 h postinjection. Sera taken before LPS administration had no TNF-alpha activity. LPS (10 micrograms/ml) and fetal, newborn, and pooled adult bovine sera alone and in combination had no direct cytotoxic effects on WEHI-164 cells. TNF-alpha cytotoxic activity is probably not due to the presence of interleukin-1 (IL-1), alpha interferon, or gamma interferon in the sera since recombinant human IL-1, natural bovine IL-1, and recombinant bovine alpha and gamma interferons had no direct cytotoxic effects on WEHI-164 cells. A monoclonal antibody that neutralizes recombinant human TNF-alpha significantly reduced the cytotoxic activity of sera from LPS-injected calves.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112564      PMCID: PMC267853          DOI: 10.1128/jcm.28.5.998-1001.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

Review 1.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

2.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

3.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

4.  Induction of circulating tumor necrosis factor cannot be demonstrated during septicemic salmonellosis in calves.

Authors:  J E Peel; M J Voirol; C Kolly; D Gobet; S Martinod
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

5.  The acute metabolic effects of tumor necrosis factor administration in humans.

Authors:  R S Warren; H F Starnes; J L Gabrilove; H F Oettgen; M F Brennan
Journal:  Arch Surg       Date:  1987-12

6.  Acute in vivo effects of human recombinant tumor necrosis factor.

Authors:  D G Remick; R G Kunkel; J W Larrick; S L Kunkel
Journal:  Lab Invest       Date:  1987-06       Impact factor: 5.662

7.  Contribution of various host factors to resistance to experimentally induced bacterial endotoxemia in calves.

Authors:  F H Michaels; K L Banks
Journal:  Am J Vet Res       Date:  1988-04       Impact factor: 1.156

8.  Cytokine appearance in human endotoxemia and primate bacteremia.

Authors:  D G Hesse; K J Tracey; Y Fong; K R Manogue; M A Palladino; A Cerami; G T Shires; S F Lowry
Journal:  Surg Gynecol Obstet       Date:  1988-02

9.  Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.

Authors:  J C Mathison; E Wolfson; R J Ulevitch
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

10.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.

Authors:  C Natanson; P W Eichenholz; R L Danner; P Q Eichacker; W D Hoffman; G C Kuo; S M Banks; T J MacVittie; J E Parrillo
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  7 in total

1.  Dysregulation of in vitro cytokine production by monocytes during sepsis.

Authors:  C Munoz; J Carlet; C Fitting; B Misset; J P Blériot; J M Cavaillon
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

2.  Differential induction of tumor necrosis factor alpha in ovine pulmonary alveolar macrophages following infection with Corynebacterium pseudotuberculosis, Pasteurella haemolytica, or lentiviruses.

Authors:  J A Ellis; M D Lairmore; D T O'Toole; M Campos
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

3.  Regulation of bovine acute phase responses by recombinant interleukin-1 beta.

Authors:  D L Godson; M E Baca-Estrada; A G Van Kessel; H P Hughes; M A Morsy; J Van Donkersgoed; R J Harland; D E Shuster; M J Daley; L A Babiuk
Journal:  Can J Vet Res       Date:  1995-10       Impact factor: 1.310

4.  Induction of inflammatory cytokines in bovine alveolar macrophages following stimulation with Pasteurella haemolytica lipopolysaccharide.

Authors:  H S Yoo; S K Maheswaran; G Lin; E L Townsend; T R Ames
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

5.  Changes in serum proteins after endotoxin administration in healthy and choline-treated calves.

Authors:  Z Yilmaz; O Eralp Inan; M Kocaturk; A T Baykal; O Hacariz; I Hatipoglu; A Tvarijonaviciute; M Cansev; J Ceron; I H Ulus
Journal:  BMC Vet Res       Date:  2016-09-20       Impact factor: 2.741

6.  Increased pulmonary secretion of tumor necrosis factor-alpha in calves experimentally infected with bovine respiratory syncytial virus.

Authors:  C M Røntved; K Tjørnehøj; B Viuff; L E Larsen; D L Godson; L Rønsholt; S Alexandersen
Journal:  Vet Immunol Immunopathol       Date:  2000-10-31       Impact factor: 2.046

7.  Acute phase responses induced in dwarf goats by r.BolL(-1beta), r.BolL(-2) and r.BolFN(-gamma).

Authors:  C T Duin; T Wensing; A S Miert
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.